Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice

Xi Zheng, Xiao Xing Cui, Zhi Gao, Michael Verano, Mou Tuan Huang, Yue Liu, Arnold Rabson, Allan H. Conney

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

In the present study, the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) alone or in combination with gemcitabine on the growth of Panc-1 pancreatic cancer cells cultured in vitro or grown in NCr immunodeficient nude mice were investigated. Combinations of TPA and gemcitabine synergistically inhibited the growth and induced apoptosis in Panc-1 cells. The combination of TPA (0.16 nM) and gemcitabine (0.5 μM) induced a marked increase in phosphorylated c-Jun NH2-terminal kinase (JNK) in the Panc-1 cells. In animal experiments, NCr nude mice with established Panc-1 tumors received daily intraperitoneal (i.p.) injections of TPA (50 ng/g body weight/day) or gemcitabine (0.5 μg/g body weight/day) alone or in combination for 26 days. Treatment with daily i.p. injections of low doses of TPA or gemcitabine alone had a modest inhibitory effect on the growth of the tumors. However, the combination of low doses of TPA and gemcitabine more potently inhibited the growth of Panc-1 tumors than either agent used individually. Treatment with TPA or gemcitabine alone or in combination did not affect the body weight of the animals. Clinical trials with TPA alone or in combination with gemcitabine on patients with pancreatic cancer are warranted in order to confirm our results.

Original languageEnglish (US)
Pages (from-to)2269-2275
Number of pages7
JournalInternational journal of oncology
Volume41
Issue number6
DOIs
StatePublished - Dec 1 2012

Fingerprint

gemcitabine
Tetradecanoylphorbol Acetate
Pancreatic Neoplasms
Cultured Cells
Neoplasms
Body Weight
Growth
Intraperitoneal Injections
Nude Mice
In Vitro Techniques
JNK Mitogen-Activated Protein Kinases

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Keywords

  • Chemotherapy
  • Gemcitabine
  • Pancreatic cancer
  • Phorbol ester
  • c-Jun NH2-terminal kinase

Cite this

@article{8083328fe40543249cb2c7a802c726dc,
title = "Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice",
abstract = "In the present study, the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) alone or in combination with gemcitabine on the growth of Panc-1 pancreatic cancer cells cultured in vitro or grown in NCr immunodeficient nude mice were investigated. Combinations of TPA and gemcitabine synergistically inhibited the growth and induced apoptosis in Panc-1 cells. The combination of TPA (0.16 nM) and gemcitabine (0.5 μM) induced a marked increase in phosphorylated c-Jun NH2-terminal kinase (JNK) in the Panc-1 cells. In animal experiments, NCr nude mice with established Panc-1 tumors received daily intraperitoneal (i.p.) injections of TPA (50 ng/g body weight/day) or gemcitabine (0.5 μg/g body weight/day) alone or in combination for 26 days. Treatment with daily i.p. injections of low doses of TPA or gemcitabine alone had a modest inhibitory effect on the growth of the tumors. However, the combination of low doses of TPA and gemcitabine more potently inhibited the growth of Panc-1 tumors than either agent used individually. Treatment with TPA or gemcitabine alone or in combination did not affect the body weight of the animals. Clinical trials with TPA alone or in combination with gemcitabine on patients with pancreatic cancer are warranted in order to confirm our results.",
keywords = "Chemotherapy, Gemcitabine, Pancreatic cancer, Phorbol ester, c-Jun NH2-terminal kinase",
author = "Xi Zheng and Cui, {Xiao Xing} and Zhi Gao and Michael Verano and Huang, {Mou Tuan} and Yue Liu and Arnold Rabson and Conney, {Allan H.}",
year = "2012",
month = "12",
day = "1",
doi = "10.3892/ijo.2012.1651",
language = "English (US)",
volume = "41",
pages = "2269--2275",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "6",

}

Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice. / Zheng, Xi; Cui, Xiao Xing; Gao, Zhi; Verano, Michael; Huang, Mou Tuan; Liu, Yue; Rabson, Arnold; Conney, Allan H.

In: International journal of oncology, Vol. 41, No. 6, 01.12.2012, p. 2269-2275.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice

AU - Zheng, Xi

AU - Cui, Xiao Xing

AU - Gao, Zhi

AU - Verano, Michael

AU - Huang, Mou Tuan

AU - Liu, Yue

AU - Rabson, Arnold

AU - Conney, Allan H.

PY - 2012/12/1

Y1 - 2012/12/1

N2 - In the present study, the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) alone or in combination with gemcitabine on the growth of Panc-1 pancreatic cancer cells cultured in vitro or grown in NCr immunodeficient nude mice were investigated. Combinations of TPA and gemcitabine synergistically inhibited the growth and induced apoptosis in Panc-1 cells. The combination of TPA (0.16 nM) and gemcitabine (0.5 μM) induced a marked increase in phosphorylated c-Jun NH2-terminal kinase (JNK) in the Panc-1 cells. In animal experiments, NCr nude mice with established Panc-1 tumors received daily intraperitoneal (i.p.) injections of TPA (50 ng/g body weight/day) or gemcitabine (0.5 μg/g body weight/day) alone or in combination for 26 days. Treatment with daily i.p. injections of low doses of TPA or gemcitabine alone had a modest inhibitory effect on the growth of the tumors. However, the combination of low doses of TPA and gemcitabine more potently inhibited the growth of Panc-1 tumors than either agent used individually. Treatment with TPA or gemcitabine alone or in combination did not affect the body weight of the animals. Clinical trials with TPA alone or in combination with gemcitabine on patients with pancreatic cancer are warranted in order to confirm our results.

AB - In the present study, the effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) alone or in combination with gemcitabine on the growth of Panc-1 pancreatic cancer cells cultured in vitro or grown in NCr immunodeficient nude mice were investigated. Combinations of TPA and gemcitabine synergistically inhibited the growth and induced apoptosis in Panc-1 cells. The combination of TPA (0.16 nM) and gemcitabine (0.5 μM) induced a marked increase in phosphorylated c-Jun NH2-terminal kinase (JNK) in the Panc-1 cells. In animal experiments, NCr nude mice with established Panc-1 tumors received daily intraperitoneal (i.p.) injections of TPA (50 ng/g body weight/day) or gemcitabine (0.5 μg/g body weight/day) alone or in combination for 26 days. Treatment with daily i.p. injections of low doses of TPA or gemcitabine alone had a modest inhibitory effect on the growth of the tumors. However, the combination of low doses of TPA and gemcitabine more potently inhibited the growth of Panc-1 tumors than either agent used individually. Treatment with TPA or gemcitabine alone or in combination did not affect the body weight of the animals. Clinical trials with TPA alone or in combination with gemcitabine on patients with pancreatic cancer are warranted in order to confirm our results.

KW - Chemotherapy

KW - Gemcitabine

KW - Pancreatic cancer

KW - Phorbol ester

KW - c-Jun NH2-terminal kinase

UR - http://www.scopus.com/inward/record.url?scp=84869764138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869764138&partnerID=8YFLogxK

U2 - 10.3892/ijo.2012.1651

DO - 10.3892/ijo.2012.1651

M3 - Article

C2 - 23041978

AN - SCOPUS:84869764138

VL - 41

SP - 2269

EP - 2275

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 6

ER -